Generates a significant amount of O2 both in vitro and in vivo, effectively alleviating tumor hypoxia, reduces the expression of hypoxia-related proteins, including HIF-1α, VEGF, and MMP-2, enhances the radiosensitivity of 125I brachytherapy. The gene discussed is VEGFA; the disease is neoplasm.